Want to see AU:MEM full AI Analyst Report?
Top Page
Memphasys Ltd
(Sydney:MEM)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.01
▲(66.67% Upside)
Action:Upgraded
Date:09/06/26
The score is primarily constrained by weak financial performance: ongoing losses, deteriorating margins, and persistent cash burn that increases funding and dilution risk, despite improving revenue growth. Valuation is also pressured because the company is loss-making (negative P/E) and no dividend support is available. Technicals contribute minimally due to missing indicator data, resulting in a near-neutral technical component.
Positive Factors
Revenue Growth
The strong revenue growth indicates increasing demand for Memphasys's fertility technologies, suggesting successful market penetration and potential for future sales expansion.
Negative Factors
Profitability Challenges
Ongoing profitability issues may hinder Memphasys's ability to reinvest in growth and innovation, potentially impacting its long-term financial health and competitive position.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The strong revenue growth indicates increasing demand for Memphasys's fertility technologies, suggesting successful market penetration and potential for future sales expansion.
Read all positive factors
Memphasys Ltd (MEM) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$18.52M
Dividend YieldN/A
Average Volume (3M)17.19M
Price to Earnings (P/E)―
Beta (1Y)0.14
Revenue Growth7299.81%
EPS Growth39.29%
CountryAU
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,087,233,600
10 Day Avg. Volume17,186,563
30 Day Avg. Volume17,186,563
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)3.54
Price to Sales (P/S)54.54
P/FCF Ratio-5.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Memphasys Ltd Business Overview & Revenue Model
Company Description
Memphasys Limited, an Australian enterprise, is dedicated to the development, manufacturing, and distribution of advanced cell and protein separation technologies, alongside associated consumable goods, for the healthcare, veterinary, and biotechn...
How the Company Makes Money
Memphasys’ intended revenue model is primarily based on commercialising its reproductive technology device platform, led by the Felix System, for use by fertility clinics and ART providers. In practice, the company can generate revenue through (i)...
Memphasys Ltd Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 273.79K | 526.92K | 60.00K | 15.37K | 27.15K |
| Gross Profit | -1.52M | 431.06K | -1.57M | -824.86K | -922.60K |
| EBITDA | -3.56M | -2.57M | -4.24M | -2.36M | -1.39M |
| Net Income | -4.10M | -4.94M | -4.44M | -3.40M | -2.08M |
Balance Sheet | |||||
| Total Assets | 11.24M | 11.02M | 12.43M | 14.67M | 14.12M |
| Cash, Cash Equivalents and Short-Term Investments | 1.18M | 298.30K | 277.80K | 637.83K | 311.83K |
| Total Debt | 4.24M | 5.11M | 4.81M | 6.37M | 5.56M |
| Total Liabilities | 7.02M | 5.65M | 5.59M | 7.28M | 6.47M |
| Stockholders Equity | 4.21M | 5.37M | 6.84M | 7.38M | 7.65M |
Cash Flow | |||||
| Free Cash Flow | -2.49M | -2.41M | -3.87M | -3.23M | -2.61M |
| Operating Cash Flow | -2.49M | -2.41M | -3.23M | -1.41M | 311.82K |
| Investing Cash Flow | -3.38K | -673.28K | -711.05K | -1.98M | -3.08M |
| Financing Cash Flow | 3.37M | 3.15M | 3.54M | 3.75M | 1.03M |
Memphasys Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$61.01M | 27.29 | 52.84% | 9.33% | 18.31% | 18.65% | |
56 Neutral | AU$315.60M | 42.41 | 2.95% | 3.05% | -0.90% | -70.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$231.74M | -14.58 | -5.34% | 2.79% | 1.84% | -178.23% | |
47 Neutral | AU$19.76M | -1.41 | -35.10% | ― | -9.10% | 31.75% | |
46 Neutral | AU$18.52M | -3.75 | -99.67% | ― | 7299.81% | 39.29% | |
45 Neutral | AU$17.15M | -4.52 | -48.97% | ― | 40.65% | 45.45% |
* Healthcare Sector Average
AU:MEM
Memphasys Ltd
―
―
―
AU:PGC
Paragon Care Limited
0.13
-0.20
-60.61%
AU:AT1
Atomo Diagnostics Ltd.
0.02
>-0.01
-10.00%
AU:CTE
Cryosite Limited
1.25
0.39
45.35%
AU:GSS
Genetic Signatures Ltd.
0.08
-0.19
-70.00%
AU:MVF
Monash IVF Group Ltd
0.82
0.14
20.59%
Memphasys Ltd Corporate Events
Memphasys to Brief Investors on Global Rollout of Felix Fertility Device
Sep 4, 2026
Memphasys Limited has invited shareholders to an investor webinar titled Lynx Discovery Series: Health Innovation, where Non-Executive Director and Commercialisation Committee Chair Marjan Mikel will provide an update on the company and its Felix ...
Memphasys Wins Turkish Approval for Felix System, Launches Commercial Sales
Sep 2, 2026
Memphasys Limited has secured product registration for its Felix System in Turkey, allowing exclusive regional partner ITL to begin commercial sales of Felix cartridges and consoles in the country. An initial order of 100 cartridges and two consol...
Memphasys Options Lapse, Trimming Potential Future Dilution
Sep 2, 2026
Memphasys Limited has announced the cessation of 31,250,000 MEMAW listed options, which carried an exercise price of $0.011 and an expiry date of 28 August 2026. The options lapsed without being exercised or converted, resulting in their removal f...
Memphasys Seals €526,500 Nordic Deal to Grow Felix™ in Europe
Sep 1, 2026
Memphasys Limited has signed an exclusive commercialisation agreement with Denmark-based NOVIVITAE ApS to distribute the Felix™ System across Denmark, Sweden, Norway, Finland and Iceland. The deal adds the Nordic states to existing arrangeme...
Memphasys Narrows Loss as Felix Sales Scale but Auditor Flags Going Concern Risk
Aug 31, 2026
Memphasys Ltd reported a narrowed audited net loss of $4.1 million for the year to 30 June 2026, down from $5.0 million a year earlier, with underlying EBITDA improving to a loss of $3.2 million from $3.8 million. The company did not declare any d...
Memphasys Accelerates Felix Launch After Early Thai FDA Approval
Aug 27, 2026
Memphasys Limited has secured early approval from the Thai Food and Drug Administration for its Felix System, clearing the way for commercial sales across Thailand under an exclusive three-year distribution agreement with IVF Envimed. The deal, wi...
Memphasys Secures Vietnam Registration for Felix System, Triggers First Major Order
Aug 19, 2026
Memphasys Ltd, an Australian reproductive biotech specialist, is commercialising its Felix System, a patented sperm selection technology designed to improve outcomes in assisted reproduction and reduce lab time. The system aims to displace convent...
Memphasys builds momentum as Felix sperm selection system gains clinical and commercial traction
Aug 9, 2026
Memphasys has showcased pivotal clinical data for its Felix sperm selection system to a major scientific audience at the Fertility Society of Australia and New Zealand 2026 conference, highlighting superior embryo utilisation rates compared with d...
Memphasys Plans 8 Million-Share Placement on ASX
Jul 22, 2026
Memphasys Limited, trading on the ASX as MEM, is a biotechnology and medical technology company focused on reproductive and life-science solutions. Its capital structure is based on ordinary fully paid shares listed on the Australian Securities Ex...
Memphasys Moves General Meeting Online and Shifts to Digital Shareholder Communication
Jul 22, 2026
Memphasys Limited has called a virtual General Meeting of shareholders for 21 August 2026, to be held via webinar at 2:00pm AEST, with shareholders encouraged to lodge proxy forms in advance. The company is leveraging recent changes to the Corpora...
Memphasys Deepens Director’s Role with New Executive Consulting Agreement
Jul 6, 2026
Memphasys Limited has entered into a consulting agreement with Mikel Enterprises Pty Ltd, an entity associated with director Marjan Mikel, under which Mr Mikel will take on an executive consulting role. He will provide strategic advisory services ...
Memphasys seals exclusive Thailand Felix deal, lifting FY2026 contracted revenue
Jul 1, 2026
Memphasys has signed an exclusive three-year distribution agreement with Bangkok-based IVF Envimed for its Felix sperm separation system in Thailand, a market of 110 registered IVF clinics performing an estimated 20,000 to 30,000 IVF cycles annual...
Memphasys Issues 240 Million Shares to Fund Growth of Fertility Technology
Jun 26, 2026
Memphasys Limited has issued 240,000,000 fully paid ordinary shares at $0.005 each to sophisticated and professional investors as part of a placement previously announced to the market. The company confirms the shares were issued without a prospec...
Memphasys seeks ASX quotation for 240 million new shares
Jun 26, 2026
Memphasys Ltd has applied for quotation on the ASX of 240 million new ordinary fully paid shares, with an issue date of June 26, 2026. The application, lodged as a new announcement under Appendix 2A, follows previously notified transactions and si...
Memphasys accelerates UK IVF rollout of Felix System after rapid clinic uptake
Jun 25, 2026
Memphasys has accelerated its commercial rollout in the United Kingdom, one of the world’s largest IVF markets, with four IVF groups now actively commercial trialling the Felix System and initial orders placed within weeks of first engagemen...
Memphasys Secures Landmark Monash IVF Deal to Drive Global Expansion
Jun 24, 2026
Memphasys has secured the largest commercial agreement in its history with Monash IVF, anchoring a new phase of commercial execution for its fertility technology platform. The deal underpins a recurring revenue model built around consoles and sing...
Memphasys to brief investors on global rollout of Felix System and growth plans
Jun 23, 2026
Memphasys Limited will host an investor webinar on 24 June 2026 to update shareholders on its commercial progress, regulatory achievements and growth trajectory as it advances global rollout of the Felix System and a recurring cartridge revenue mo...
Memphasys Plans Major Share and Options Issue on ASX
Jun 18, 2026
Memphasys Limited has notified the ASX of a proposed capital raising via a placement or other type of securities issue. The company plans to issue up to 240,000,000 fully paid ordinary shares and 2,500,000 unlisted options, with the issue date tar...
Memphasys raises $1.2m and extends note as Felix rollout accelerates
Jun 18, 2026
Memphasys Limited has raised $1.2 million via a share placement at $0.005 per share, fully utilising its existing placement capacity, to fund the commercial rollout of its Felix sperm separation system and build inventory for rising demand. The ra...
Memphasys seals exclusive national Felix™ supply deal with Monash IVF
Jun 16, 2026
Memphasys has signed a 12‑month exclusive national supply agreement with Monash IVF Group for its Felix™ automated sperm selection system, following inclusion of the device on the Australian Register of Therapeutic Goods. The deal, whi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.